166 related articles for article (PubMed ID: 27816773)
1. The soluble guanylyl cyclase activator BAY 60-2770 inhibits murine allergic airways inflammation and human eosinophil chemotaxis.
Baldissera L; Squebola-Cola DM; Calixto MC; Lima-Barbosa AP; Rennó AL; Anhê GF; Condino-Neto A; De Nucci G; Antunes E
Pulm Pharmacol Ther; 2016 Dec; 41():86-95. PubMed ID: 27816773
[TBL] [Abstract][Full Text] [Related]
2. Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway.
Mendes-Silverio CB; Leiria LO; Morganti RP; Anhê GF; Marcondes S; Mónica FZ; De Nucci G; Antunes E
PLoS One; 2012; 7(11):e47223. PubMed ID: 23144808
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterisation of the relaxation induced by the soluble guanylate cyclase activator, BAY 60-2770 in rabbit corpus cavernosum.
Estancial CS; Rodrigues RL; De Nucci G; Antunes E; Mónica FZ
BJU Int; 2015 Oct; 116(4):657-64. PubMed ID: 25715977
[TBL] [Abstract][Full Text] [Related]
4. Prolonged therapy with the soluble guanylyl cyclase activator BAY 60-2770 restores the erectile function in obese mice.
Silva FH; Leiria LO; Alexandre EC; Davel AP; Mónica FZ; De Nucci G; Antunes E
J Sex Med; 2014 Nov; 11(11):2661-70. PubMed ID: 25196910
[TBL] [Abstract][Full Text] [Related]
5. Soluble guanylyl cyclase (sGC) degradation and impairment of nitric oxide-mediated responses in urethra from obese mice: reversal by the sGC activator BAY 60-2770.
Alexandre EC; Leiria LO; Silva FH; Mendes-Silvério CB; Calmasini FB; Davel AP; Mónica FZ; De Nucci G; Antunes E
J Pharmacol Exp Ther; 2014 Apr; 349(1):2-9. PubMed ID: 24421320
[TBL] [Abstract][Full Text] [Related]
6. Soluble guanylate cyclase as an alternative target for bronchodilator therapy in asthma.
Ghosh A; Koziol-White CJ; Asosingh K; Cheng G; Ruple L; Groneberg D; Friebe A; Comhair SA; Stasch JP; Panettieri RA; Aronica MA; Erzurum SC; Stuehr DJ
Proc Natl Acad Sci U S A; 2016 Apr; 113(17):E2355-62. PubMed ID: 27071111
[TBL] [Abstract][Full Text] [Related]
7. The soluble guanylyl cyclase activator BAY 60-2770 ameliorates overactive bladder in obese mice.
Leiria LO; Silva FH; Davel AP; Alexandre EC; Calixto MC; De Nucci G; Mónica FZ; Antunes E
J Urol; 2014 Feb; 191(2):539-47. PubMed ID: 24050894
[TBL] [Abstract][Full Text] [Related]
8. A new compound, 1H,8H-pyrano[3,4-c]pyran-1,8-dione, suppresses airway epithelial cell inflammatory responses in a murine model of asthma.
Lee H; Han AR; Kim Y; Choi SH; Ko E; Lee NY; Jeong JH; Kim SH; Bae H
Int J Immunopathol Pharmacol; 2009; 22(3):591-603. PubMed ID: 19822076
[TBL] [Abstract][Full Text] [Related]
9. Inhibitory effects on human eosinophil chemotaxis in vitro by BAY 41-2272, an activator of nitric oxide-independent site of soluble guanylate cyclase.
Thomazzi SM; Moreira J; De Nucci G; Antunes E
Biochem Pharmacol; 2005 Mar; 69(6):875-82. PubMed ID: 15748699
[TBL] [Abstract][Full Text] [Related]
10. BAY 60-2770 activates two isoforms of nitric oxide sensitive guanylyl cyclase: Evidence for stable insertion of activator drugs.
Sömmer A; Sandner P; Behrends S
Biochem Pharmacol; 2018 Jan; 147():10-20. PubMed ID: 29155144
[TBL] [Abstract][Full Text] [Related]
11. NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size.
Bice JS; Keim Y; Stasch JP; Baxter GF
Cardiovasc Res; 2014 Feb; 101(2):220-8. PubMed ID: 24259501
[TBL] [Abstract][Full Text] [Related]
12. Soluble guanylate cyclase modulators blunt hyperoxia effects on calcium responses of developing human airway smooth muscle.
Britt RD; Thompson MA; Kuipers I; Stewart A; Vogel ER; Thu J; Martin RJ; Pabelick CM; Prakash YS
Am J Physiol Lung Cell Mol Physiol; 2015 Sep; 309(6):L537-42. PubMed ID: 26254425
[TBL] [Abstract][Full Text] [Related]
13. Effects of hydrogen peroxide on relaxation through the NO/sGC/cGMP pathway in isolated rat iliac arteries.
Tawa M; Shimosato T; Iwasaki H; Imamura T; Okamura T
Free Radic Res; 2015; 49(12):1479-87. PubMed ID: 26334090
[TBL] [Abstract][Full Text] [Related]
14. Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells.
Zenzmaier C; Kern J; Heitz M; Plas E; Zwerschke W; Mattesich M; Sandner P; Berger P
Exp Cell Res; 2015 Nov; 338(2):162-9. PubMed ID: 26410556
[TBL] [Abstract][Full Text] [Related]
15. A novel soluble guanylyl cyclase activator, BR 11257, acts as a non-stabilising partial agonist of sGC.
Elgert C; Rühle A; Sandner P; Behrends S
Biochem Pharmacol; 2019 May; 163():142-153. PubMed ID: 30753814
[TBL] [Abstract][Full Text] [Related]
16. Responsiveness of rat aorta and pulmonary artery to cGMP generators in the presence of thiol or heme oxidant.
Tawa M; Yamashita Y; Masuoka T; Nakano K; Yoshida J; Nishio M; Ishibashi T
J Pharmacol Sci; 2019 May; 140(1):43-47. PubMed ID: 31036520
[TBL] [Abstract][Full Text] [Related]
17. Chronological Change of Vascular Reactivity to cGMP Generators in the Balloon-Injured Rat Carotid Artery.
Tawa M; Shimosato T; Sakonjo H; Masuoka T; Nishio M; Ishibashi T; Okamura T
J Vasc Res; 2019; 56(3):109-116. PubMed ID: 31085923
[TBL] [Abstract][Full Text] [Related]
18. Preconditioning with soluble guanylate cyclase activation prevents postischemic inflammation and reduces nitrate tolerance in heme oxygenase-1 knockout mice.
Wang WZ; Jones AW; Wang M; Durante W; Korthuis RJ
Am J Physiol Heart Circ Physiol; 2013 Aug; 305(4):H521-32. PubMed ID: 23771693
[TBL] [Abstract][Full Text] [Related]
19. Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41-2272 and BAY 60-2770 alone or in combination with a phosphodiesterase type 5 inhibitor.
Füllhase C; Hennenberg M; Sandner P; Strittmatter F; Niedworok C; Bauer RM; Gratzke C; Soler R; Stief C; Andersson KE
Neurourol Urodyn; 2015 Nov; 34(8):787-93. PubMed ID: 25230878
[TBL] [Abstract][Full Text] [Related]
20. Pressure-overload-induced subcellular relocalization/oxidation of soluble guanylyl cyclase in the heart modulates enzyme stimulation.
Tsai EJ; Liu Y; Koitabashi N; Bedja D; Danner T; Jasmin JF; Lisanti MP; Friebe A; Takimoto E; Kass DA
Circ Res; 2012 Jan; 110(2):295-303. PubMed ID: 22095726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
